-
12:46:19 AM
Sign in with email
Forgot your password?
Register with email
Account Verification

MRK Stock News

05/24/22 6:45 AM
NYSE : MRK
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced or Early-Stage Triple-Negative Breast Cancer at High Risk of Recurrence
Merck, known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA, Merck’ s anti-PD-1 therapy, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery for adults with locally advanced or early-stage triple-negative breast...
RHEA-AI
very positive
05/20/22 8:15 AM
NYSE : MRK
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection
Merck, known as MSD outside the United States and Canada, today announced that the European Medicines Agency’ s Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of KEYTRUDA, Merck’ s anti-PD-1 therapy, as monotherapy for the adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB or IIC...
RHEA-AI
very positive
05/10/22 6:45 AM
NYSE : MRK
conferences
Merck To Present Data at 2022 ASCO Annual Meeting Highlighting Promising Pipeline Medicines and Significant Progress in Treating Earlier Stages of Certain Cancers With KEYTRUDA® (pembrolizumab)
Merck, known as MSD outside the United States and Canada, today announced that data for six approved medicines and pipeline candidates in more than 25 types of cancer will be presented at the 2022 American Society of Clinical Oncology Annual Meeting in Chicago from June 3-7. Additionally, Merck will present data from its diverse pipeline of...
RHEA-AI
neutral
04/29/22 6:45 AM
NYSE : MRK
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Deficient Mismatch Repair (dMMR) Tumors in Five Different Types of Cancer
Merck, known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA, Merck’ s anti-PD-1 therapy, as monotherapy for the treatment of microsatellite instability-high or deficient mismatch repair tumors in adults with: unresectable or metastatic colorectal cancer after previous...
RHEA-AI
neutral
04/29/22 6:30 AM
NYSE : MRK
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)
Merck, known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA, Merck’ s anti-PD-1 therapy, in combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent or metastatic cervical cancer in adults whose tumors express PD-L1. Nicoletta Colombo, associate...
RHEA-AI
neutral
04/25/22 6:45 AM
NYSE : MRK
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced, or High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
Merck, known as MSD outside the United States and Canada, today announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of KEYTRUDA, Merck’ s anti-PD-1 therapy, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant...
RHEA-AI
positive